Top Markets
#1 Siacoin Siacoin +18.72%
#2 Cash Cat Cash Cat +12.00%
#3 Seeker Seeker +10.47%
#4 DogBull DogBull +9.87%
#5 0G 0G +7.70%
#6 Story Story +5.49%
#7 The Black Bull The Black Bull +5.17%
#8 Useless Coin Useless Coin +5.06%
#9 The Bitcoin Bull The Bitcoin Bull +4.99%
#10 Linea Linea +4.75%
Coin of the day
Siacoin Siacoin
Settings
Language
ENGLISH
Currency
USD
Theme
Valerio Therapeutics S.A. Valerio Therapeutics S.A.

Valerio Therapeutics S.A.

ALVIO
Rank in Stocks #14047
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A.... Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Share Price
$0.88012714
Last synced: 2026-08-31
Market Cap
$439.58M
Change (1 day)
-4.01%
Change (1 year)
1,131.97%
Country
FR
Trade Valerio Therapeutics S.A. (ALVIO)

Category

Healthcare
P/E ratio for Valerio Therapeutics S.A. (ALVIO)
P/E ratio as of 2026 TTM: 0
According to Valerio Therapeutics S.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Valerio Therapeutics S.A. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.